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Abstract
Pre-fibrotic myelofibrosis (pre-PMF) and essential thrombocythemia (ET) are characterized by similarly increased rate of
thrombotic events, but no study specifically analyzed risk factors for thrombosis in pre-PMF. In a multicenter cohort of
382 pre-PMF patients collected in this study, the rate of arterial and venous thrombosis after diagnosis was 1.0 and
0.95% patients/year. Factors significantly associated with arterial thrombosis were age, leukocytosis, generic
cardiovascular risk factors, JAK2V617F and high molecular risk mutations, while only history of previous thrombosis,
particularly prior venous thrombosis, was predictive of venous events. The risk of total thromboses was accurately
predicted by the the international prognostic score for thrombosis in essential thrombocythemia (IPSET) score,
originally developed for ET, and corresponded to 0.67, 2.05, and 2.95% patients/year in the low-, intermediate-, and
high-risk categories. IPSET was superior to both the conventional 2-tiered score and the revised IPSET in this cohort of
pre-PMF patients. We conclude that IPSET score can be conveniently used for thrombosis risk stratification in patients
with pre-PMF and might represent the basis for individualized management aimed at reducing the increased risk of
major cardiovascular events. Further refinement of the IPSET score in pre-PMF might be pursued by additional,
prospective studies evaluating the inclusion of leukocytosis and/or adverse mutational profile as novel variables.
Introduction
The revised 2016 World Health Organization (WHO)
classification of myeloproliferative neoplasms recognized
prefibrotic myelofibrosis (pre-PMF) as an entity distinct
from essential thrombocythemia (ET)1–3. While the initial
presentation of pre-PMF is often isolated thrombocytosis,
thereby mimicking ET, the course of pre-PMF may be
highly symptomatic, and outcome is worse than ET4,5.
Patients with pre-PMF have higher leukocyte and platelet
counts, lower hemoglobin, higher lactate dehydrogenase
levels, and more frequently splenomegaly compared with
patients with ET4. In the largest series available, including
661 patients with pre-PMF, the median overall survival
(OS) of pre-PMF was 14.7 years, significantly shorter than
30.2 years in a parallel cohort of 421 unselected patients
with ET, accounting for a hazard ratio (HR) of 2.7 (95%
confidence interval (CI), 1.9–3.7)4. Conversely, ET and
pre-PMF have comparable risk of cardiovascular events.
In one study that considered 180 patients with pre-PMF,
the cumulative risk of thrombotic complications was
25.4% compared with 21.5% in 891 ET patients,
accounting for a rate of overall major thrombosis of 1.9
and 1.7% patients/year, respectivey6. In another study on
109 pre-PMF patients, the 10-year cumulative incidence
of thrombosis was 18.5% (95%CI, 10.7–27.8) compared
with 18% (95%CI, 0.4–6.0) in 269 patients with ET7.
Prediction of thrombosis risk in ET currently relies on
two different models. The conventional two-tiered model
includes age >60 years and history of thrombosis, and
stratifies patients in a low- and high-risk category with
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rate of thrombotic events of 0.95 and 2.86% patients/
year8. More recently, following elucidation of the asso-
ciation of driver mutations with thrombotic risk9,10, a new
scoring system, the international prognostic score for
thrombosis in essential thrombocythemia (IPSET), was
developed; IPSET enlists age >60 years, thrombosis his-
tory, cardiovascular risk factors and JAK2V617F mutation
as the variables that allowed to separate patients into a
low, intermediate, and high-risk category, with respective
risk of thrombosis of 1.03, 2.35, and 3.56% patients/
years8,11. The IPSET score was validated in an external
validation cohort of 329 patients8 as well as an indepen-
dent series of 585 patients from the Mayo Clinic12; it was
also validated in a population of ET patients from China13.
IPSET was subsequently revised to identify a very low-risk
category of patients, which includes younger patients
without history of thrombosis and lacking the JAK2V617F
mutation12,14. The IPSET-revised and/or IPSET is
recommended by recent guidelines, including those from
the European Leukemia Net and the National Compre-
hensive Cancer Network, as the most appropriate risk
scoring system(s) to personalize treatment with anti-
platelet agents and/or cytoreduction, or follow up only, in
patients with ET15,16. On the opposite, no score has been
specifically developed to assess thrombotic risk in pre-
PMF, reflecting difficulties and variability in the man-
agement of this condition by hematologists17. Further-
more, it has not been addressed yet whether the available
scores for ET may be informative in patients with pre-
PMF as well; this question was the objective of
current work.
Materials and methods
Study population
Clinical and hematologic information of 382 con-
secutive patients with a diagnosis of pre-PMF were col-
lected from four Italian tertiary centers (Florence, Pavia,
Bergamo, Rome). Patients’ eligibility criteria included
revised diagnosis according to 2016 WHO criteria and
known genotype for JAK2V617F, MPLW515L/K, Calre-
ticulin (CALR) mutation1. The study was approved by
each Institutional Review Board, and was conducted
according to Helsinki declaration; written, informed
consent was obtained from all living subjects. In a group
of patients (n= 132), information regarding high mole-
cular risk (HMR) mutations, including ASXL1, EZH2,
SRSF2, IDH1/2, were available; there was no specific
predefined criteria for HMR analysis, so these patients
were randomly analyzed in the different centers’ cohorts.
Histopathology, hematologic and clinical data were care-
fully reviewed in each case and diagnosis was confirmed
based on the revised 2016 WHO criteria. Histopathology
analysis was performed locally, blinded of patient’s history
and clinical information except for sex and age. Clinical
and hematologic information were coincident
(±12 months) with the diagnostic biopsy.
Mutation analysis
Analysis was performed on DNA from peripheral blood
granulocytes collected at diagnosis or within 1 year, as
concerned driver mutations, and up to 4 years after
diagnosis (median, 19 months, range 0–46 months) for
HMR mutations. JAK2V617F mutation was assessed by
real-time quantitative PCR; for MPL mutations, high-
resolution melting analysis and bidirectional Sanger
sequencing were employed; MPL515x indicates any
mutation at codon 5159. CALR mutations were identified
by capillary electrophoresis and bidirectional sequencing,
and classified as type 1/type 1-like or type 2/type 2-
like18,19. Patients lacking mutations in the three driver
genes were defined as “triple negative” (TN). A next
generation sequencing approach with the PGM Ion Tor-
rent platform was used to detect mutations across the
entire coding region of EZH2 and ASXL1, and mutation
hotspots for IDH1, IDH2, and SRSF2. An HMR category
was defined by presence of at least one of the above
mutations, as reported previously20,21; information on
other myeloid neoplasm associated mutations with
potential prognostic impact, such as U2AF122, were not
available. In case of variants not previously reported, only
those considered potentially damaging by Polyphen and
SIFT algorithm were included in the database. Genotyp-
ing for driver mutations was performed locally, while
analysis of HMR mutations was centralized (CRIMM,
Florence).
Statistical analysis
Thrombosis‐free survival was determined from diag-
nosis to the first thrombotic event. In case of thrombotic
events before establishment of diagnosis of pre-PMF, only
those occurred in the previous 3 years were considered.
Cox-regression analysis was used for multivariable ana-
lysis. Patients were stratified according to the conven-
tional two-tiered risk stratification system23, IPSET‐
thrombosis8 and revised IPSET‐thrombosis14 model.
Harrell’s concordance (C) statistic was calculated to
measure the predictive accuracy of different models. A
P < 0.05 was considered statistically significant.
Results
A total of 382 patients were included; their clinical and
hematologic characteristics at diagnosis are reported in
Table 1. Median age was 57.6 years, 45% were above the
age of 60; 51% were male. Generic cardiovascular risk
factors were present in 45%: smoking (14%), hypertension
(27%), diabetes mellitus (8%), and hypercholesterolemia
(12%). A driver mutation was found in 92%: JAK2V617F
in 65%, MPLW515L/K 4.5%, CALR type1 16.5%, and
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CALR Type2 6%; 31 patients (8%) were TN. HMR
mutations were available in 132 patients (35%); of these,
28% were HMR positive, and 8% had >2 HMR mutations
(Table 2). Overall, 239 patients (77%) received a cytor-
eductive treatment; hydroxyurea was the most commonly
used (68%). Antiplatelet agent was used in 72% of the
patients (acetylsalicylic acid 88%, clopidogrel 10%, ticlo-
pidine 1%), while 57 patients (15%) received anticoagulant
agents (vitamin K antagonists 75%, direct oral antic-
oagulants 12%, heparin 11%) (Supplementary Table 1).
After a median follow-up of 6.9 years (range, 0.08–32.6),
105 patients (27%) died. Sixty patients (16%) experienced
overt myelofibrotic progression and 29 (8%) transformed
to acute leukemia, with incidence rate of 2.05%, 0.95% and
3.41% patients/year, respectively (Table 3). Major
hemorrhages affected 3 and 7% of the patients before/at
diagnosis and during follow-up, respectively.
A major thrombotic event occurred before/at diagnosis in
65 patients (17%), including 35 arterial (9%), and 31 venous
(8%) thromboses. During the follow-up, 56 patients (15%)
developed a thrombotic event, with incidence rate of 1.99%
patients/year (95% CI 1.53–2.60); 30 were arterial (8%) and
28 venous (7%) events, accounting for incidence rate of
1.00% (95% CI 0.70–1.45) and 0.95% (95% CI 0.66–1.38)
patients/year, respectively (Table 4). The most frequent
arterial thrombosis were acute myocardial infarction and
stroke (23% each at diagnosis, 30% and 27%, respectively,
during follow up). As regarded venous events, splanchnic
vein thrombosis (SVT) represented as many as 68% of all
venous events at diagnosis, and 29% during follow up,
whereas deep venous thrombosis and pulmonary embolism
accounted for 43% of all venous events during follow up
(Table 4). In univariate analysis, factors significantly asso-
ciated with arterial thrombosis were age greater than 65
years (HR 2.88, 95%CI 1.37–6.05; P= 0.005), leukocyte
count >10 × 109/L (HR 2.43, 95%CI 1.11–5.31; P= 0.026),
presence of at least one CV risk factor (HR 2. 16, 95%CI
1.01–4.62; P= 0.047), JAK2V617F mutation (HR 3.35, 95%
CI 1.15–9.74; P= 0.027), HMR status (HR 13.1, 95% CI
Table 1 Clinical and hematologic characteristics at
diagnosis of 382 study patients with prefibrotic PMF.
Variables N
Male, n (%) 382 195 (51%)
Age, years, median (range) 382 57.6 (15.6–91.9)
Age ≥60 years, n (%) 382 170 (45)
Previous thrombosis, n (%) 382 65 (17)
Arterial 35 (9)
Venous 31 (8)
Microvascular disturbances, n (%) 370 63 (17)
Major bleeding, n (%) 382 11 (3)
Blood values
Hemoglobin, g/L, median (5th–95th percentiles) 376 135 (93–159)
Hematocrit, %, median (5th–95th percentiles) 345 41.1 (30.6–49.0)
Platelet count, ×109/L, median (5th–95th
percentiles)
380 700 (130–1481)
Leukocyte count, ×109/L, median (5th–95th
percentiles)
378 10.0 (5.0–24.1)
LDH > normal range; n (%) 300 220 (73)
Bone marrow fibrosis grade, n (%) 382
0 161 (42)
1 221 (58)
Palpable splenomegaly, n (%) 382 180 (47)
Spleen size, cm from LCM, n (%) 382
<5 cm 42 (11)
6–10 cm 42 (11)
11–15 cm 71 (19)
16–20 cm 44 (12)
>20 cm 23 (6)
CV risk factors (at least 1), n (%) 360 161 (45)
History of active/remote smoking 50 (14)
History of hypertension 97 (27)
History of diabetes mellitus 27 (8)
History of hypercholesterolemia 39 (12)
Thrombophilia, n (%) 153
Inherited 19a (12)
Acquired 30a (19)
Negative 105 (69)
Abnormal cytogenetics, n (%) 286 42 (15)
aOne patient had both inherited and acquired thrombophilia.
LCM left costal margin; CV cardiovascular.
Table 2 Mutation profile of study patients.
Variables N
Driver mutation
JAK2V617F, n (%) 378 246 (65)
VAF 225 36.8 (0.3–100)
CALR type1, n (%) 288 63 (22)
VAF 44 50 (9–63.7)
CALR type2, n (%) 134 24 (18)
VAF 21 49 (7–94)
MPL W515x, n (%) 336 17 (5)
Triple negatives, n (%) 377 31 (8)
Non-driver mutations
ASXL1, n (%) 133 28 (21)
EZH2, n (%) 132 5 (4)
SRSF2, n (%) 132 14 (11)
IDH1/2, n (%) 132 1 (1)
HMR, n (%) 132 37 (28)
HMR ≥ 2, n (%) 132 11 (8)
Data are reported as median (range).
VAF variant allele frequency, HMR high molecular risk, points to the presence of
at least one mutation in any one of ASXL1, EZH2, SRSF2, IDH1/2. HMR ≥ 2 means
the presence of two or more mutated genes among the above. Two or more
mutations in the same gene are counted as one.
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1.34–127; P= 0.027), and EZH2 mutation (HR 10.1,
1.03–99; P= 0.027). Conversely, only history of previous
thrombosis retained significance for venous thrombosis
(HR 3.06, 95% CI 1.41–6.64; P= 0.005), particularly in case
of a previous venous event (HR 5.53, 95% CI 2.32–12.20; P
< 0.0001). Male sex showed a trend (P= 0.079) toward
protection for venous events (HR= 0.49; 95%CI, 0.22–1.09)
(Table 5).
To evaluate the performance of available risk scores for
predicting thrombosis in pre-PMF, patients were first
stratified according to the conventional two-tiered risk
score. A statistically significant difference between low-
and high-risk category was observed, pointing to an
incidence rate of 1.47% and 2.71% patients/year, respec-
tively (P= 0.041) (Fig. 1, panel A); the HR for the high-
risk versus low-risk category was 1.74 (95% CI 1.02–2.99;
P= 0.044). Then, patients were stratified according to
IPSET and revised IPSET model, resulting in effective
discrimination of different categories. The rate of
thrombosis in IPSET low-, intermediate-, and high-risk
category was 0.67, 2.05 and 2.95% patients/year (P=
0.006); the HR was 2.81 and 4.14 for the intermediate- and
high-risk versus reference low-risk category (Table 6). In
the revised-IPSET very low-, low-, intermediate-, and
high-risk category, the rate of thrombosis was 0.54%,
2.23%, 2.44% and 2.69% patients/year, respectively (P=
Table 3 Major clinical events after diagnosis and
outcome in the study population (n= 382).
Events
Major thrombosis, n (%) 56 (15)
Rate % pts/year, (95% CI) 1.99 (1.53–2.60)
Arterial, n (%) 30 (8)
Rate % pts/year, (95% CI) 1.00 (0.70–1.45)
Venous, n (%) 28 (7)
Rate % pts/year, (95% CI) 0.95 (0.66–1.38)
Major bleeding, n (%) 28 (7)
Rate % pts/year, (95% CI) 0.94 (0.65–1.36)
Overt MF, n (%) 60 (16)
Rate % pts/year, (95% CI) 2.05 (1.59–2.64)
AML, n (%) 29 (8)
Rate % pts/year, (95% CI) 0.95 (0.66–1.36)
Death, n (%) 105 (27)
Rate % pts/year, (95% CI) 3.41 (2.81–4.13)
Two patients had both arterial and venous events.
Table 4 Type of thrombotic events occurring before/at
diagnosis and during follow-up.
Before/At diagnosis During follow-up
Arterial thrombosis, N 35 30
AMI 8 (23%) 9 (30%)
Stroke 8 (23%) 8 (27%)
TIA 7 (20%) 5 (17%)
PAT 7 (20%) 4 (13%)
Abdominal 4 (11%) 1 (3%)
Othera 1 (3%) 2 (7%)
Venous thrombosis, N 31 28
DVT/PE 5 (16%) 12 (43%)
Budd-Chiari 3 (10%) 2 (7%)
SVT 21 (68%) 8 (29%)
Otherb 2 (6%) −
AMI acute myocardial infarction, TIA documented transient ischemic attack, PAT
peripheral arterial thrombosis, DVT/PE deep venous thrombosis/pulmonary
embolism, SVT splanchnic vein thrombosis, including porto-mesentheric, splenic,
splanchnic venous thrombosis.
aLung, retinal.
bCerebral, retinal thrombosis.
Table 5 Predictors* of arterial, venous and total
thrombosis in univariate analysis.
Arterial thrombosis
(n= 30)
Venous thrombosis
(n= 28)
Variables HR (95% CI) P value HR (95% CI) P value
Male sex 0.49 (0.22–1.09) 0.079
Age, years 1.04 (1.01–1.07) 0.004
≥60 years 2.01 (0.96–4.21) 0.062
≥65 years 2.88 (1.37–6.05) 0.005
Previous
thrombosis
3.06 (1.41–6.64) 0.005
Arterial
Venous 5.53 (2.32–12.2) <0.0001
Leukocyte count
≥10×109/L
2.43 (1.11–5.31) 0.026
CV risk factorsa
(at least 1)
2.16 (1.01–4.62) 0.047
Driver mutations
JAK2V617F 3.35 (1.15–9.74) 0.027
Nondriver
mutations
EZH2 10.1 (1.03–99) 0.047
HMR 13.1 (1.34–127) 0.027
*Variables with a P < 0.10 in univariate analysis.
aHistory of smoking, hypertension, diabetes mellitus, hypercholesterolemia.
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0.023), with HR of 3.90, 4.14, and 4.63 versus reference
category. The corresponding thrombosis-free survival
curves are shown in Fig. 1, panel B, C.
The incremental value of incorporating new risk factors
that were identified in this study, and are not included in the
original IPSET model, was also preliminary evaluated. When
WBC> 10 × 109/L (this threshold was preliminary defined by
ROC analysis as the one having best discrimination power)
and HMR status were incorporated into the model for
arterial events, the C statistic increased significantly from the
baseline value of 0.68–0.74 after the addition of leukocyte
count >10 × 109/L (P= 0.041), to 0.81 (P= 0.023) for HMR
status and 0.91 (P= 0.006) when the HMR status plus leu-
kocytosis was added to IPSET. Conversely, inclusion of male
sex increased the C value of IPSET from 0.58 to 0.63 (P=
0.023) for venous thrombosis (Fig. 2).
Discussion
Patients with prefibrotic myelofibrosis are at about
twofold increased risk of cardiovascular events, includ-
ing major thrombosis and hemorrhage, compared with
the reference age-matched population, a figure that is
substantially similar to patients with ET. Since in ET
thrombosis represents the main cause of mortality,
scores have been developed over time to predict the
individual risk of thrombosis and facilitate the adoption
of the most appropriate therapeutic measures. Patients
with ET are conventionally stratified based upon older
age and previous thrombosis, with an intermediate
category including those with cardiovascular risk factors
only. A new score was developed recently, the IPSET
score, and a revised version (IPSET-revised), which
takes advantage of the powerful prognostic value of the
JAK2V617F mutation in addition to the classical risk
variables8,14. On the other hand, there is little infor-
mation regarding the variables that associate with
thrombosis risk in patients with pre-PMF, translating in
uncertainties regarding stratification and management
of these patients17,24.
With the aim to approach this issue, we collected a
multicenter cohort of 382, consecutive, patients with a
diagnosis of pre-PMF, carefully revised according to the
2016 WHO criteria, and we analyzed major thrombotic
events at diagnosis and during the follow-up by employing
the conventional risk score and the IPSET and IPSET-
revised score. Main results of this analysis indicate that
the IPSET score, and to a somewhat lesser degree (as
indicated by the HR values of the individual risk cate-
gories; Table 6) the IPSET-revised, effectively dis-
criminates patients with pre-PMF in a low, intermediate
(HR, 2.81 versus low-risk) and high-risk (HR 4.14) cate-
gory. The rate of thrombosis in these categories is sub-
stantially similar to those reported in patients with
ET8,12,13, and are about two- and three-fold higher than
expected in normal population.
Based on univariate analysis indicating that, in addition
to the variables enlisted in the IPSET score, also
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211 151(15) 111(9) 86(5) 60(2) 45(1)High risk
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High risk, rate: 2.71%/pts-year
by standard risk groups
Thrombosis-free survival
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0.60
0.70
0.80
0.90
1.00
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S
178 130(14) 99(9) 76(4) 51(2) 36(1)High risk
93 77(4) 62(3) 47(4) 30(0) 24(1)Intermediate risk
85 74(1) 61(2) 52(0) 43(0) 33(1)Low risk
Number at risk
0 2 4 6 8 10
Years from diagnosis
Low risk, rate: 0.67%/pts-year
Intermediate risk, rate: 2.05%/pts-year
High risk, rate: 2.95%/pts-year
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98 85(4) 70(5) 56(3) 37(1) 29(1)Low risk
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A
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C
Fig. 1 Thrombosis-free Survival Analysis. The Kaplan–Meyer
analysis of thrombosis free survival (TFS), considering all thrombotic
events after diagnosis in the 382 patients included in the study, are
shown in a, according to the conventional 2-tiered risk score (b) for
the IPSET score, and c, for the revised IPSET score.
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leukocytosis and an HMR status for arterial events, and
male sex for venous events, correlated with thrombosis
risk, we evaluated their impact in the settings of the
IPSET score itself, showing that, at variable extent, all
increased the predictive power of the model. In particular,
we noticed with interest the novel finding that the HMR
status, known to be highly informative in patients with
overt MF as concerns OS and transformation to leuke-
mia20,21,25,26, represented a powerful risk factor for
thrombosis in the settings of pre-PMF, and increased
significantly the predictive power of the IPSET model
from 0.68 to 0.91, as assessed by C-statistics. Among the
genes constituting the HMR category, EZH2 emerged as
the most statistically significant one in univariate analysis,
but due to the low number of cases it was not assessed in
multivariate analysis. However, we underline that the HR
for thrombosis of HMR mutations was wide, likely owing
to the low number of patients with the mutation(s) and
concurrent thrombotic events; these findings clearly need
to be substantiated in larger studies, with the possibility
that a revised IPSET specifically developed for pre-PMF
patients might benefit from addition of one or both
variables.
We acknowledge that there are intrinsic limitations to
this study, which include the lack of an independent
validation cohort, a central review of histopathological
specimens, yet evaluated by expert local hemopathologists
strictly adhering to 2016 WHO criteria, and the restric-
tion of analysis of HMR mutations to a subset only of the
entire population of study; both could be the objective of
future studies. However, as regards HMR mutations, we
are quite confident about the lack of any population
selection bias owing that the overall frequency of
Table 6 Performance of prognostic risk stratifications models for thrombosis.
Prognostic model N (%) Total thrombosis (n= 56)
N thrombosis HR (95% CI), P value C-statistic
Standard risk groupsa 382 0.58
Low risk 171 (45) 22 1 (ref)
High risk 211 (55) 34 1.74 (1.02–2.99), 0.044
IPSET-thrombosis risk groupsb 356 0.63
Low risk 85 (24) 5 1 (ref)
Intermediate risk 93 (26) 13 2.81 (1.00–7.91), 0.050
High risk 178 (50) 32 4.14 (1.61–10.7), 0.003
IPSET-thrombosis revised risk groupsc 370 0.62
Very low risk 72 (19) 4 1 (ref)
Low risk 98 (27) 17 3.90 (1.31–11.6), 0.014
Intermediate risk 52 (14) 7 4.14 (1.21–14.2), 0.024
High risk 148 (40) 24 4.63 (1.60–13.4), 0.005
N(%) indicates the number of patients for whom all required data were available, and the % over total (n= 382).
a“low risk” (age ≤ 60 years and no thrombosis history); “high risk” (age ≥ 60 years and/or thrombosis history).
b“low risk” (tot score 0–1); “intermediate risk” (tot score 2); “high risk” (tot score ≥ 3). Age ≥60 years and at least 1 CV risk factor (1 score); thrombosis history and JAK2
mutation (2 scores).
c“very low risk” (no thrombosis history, age ≤60 years and JAK2-unmutated); “low risk” (no thrombosis history, age ≤60 years and JAK2-mutated); intermediate risk’ (no
thrombosis history, age ≥60 years and JAK2-unmutated) and high risk (thrombosis history or age ≥60 years with JAK2 mutation).
0.68
0.74
0.81
0.91
0.58
0.63
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
ARTERIAL EVENTS
IPSET-thrombosis
+ WBC > 10 x10^9/L
+ HMR
+ Both
VENOUS EVENTS
IPSET-thrombosis
 + sex
C-stasc
P= 0.041
P= 0.023
P= 0.006
P= 0.023
Fig. 2 C-statistic Analysis. Incremental value of C-statistic by new risk
factors added to the IPSET prognostic risk scoring model for arterial
(leukocytosis, high mutation risk (HMR) status, and both) and venous
(male sex) events. P values quoted are calculated testing the
difference on coefficients of the Cox-regression models.
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individual mutations was overall comparable to what
reported in another series of 278 pre-PMF patients4. We
also acknowledge that more extensive mutation analysis,
using gene panels larger than the one originally designed
for assessing HMR mutations, could permit to identify
novel somatic variables associated with thrombotic risk in
pre-PMF patients, for example TET2 mutations as shown
in subjects with age-related clonal hematopoiesis27.
Finally, we cannot exclude at this time that the high
proportion of splancnic thrombosis among the venous
events recorded at diagnosis represents a bias of referral
due to the tertiary nature of the involved centers, an
observation that needs however to be revisited. This high
rate of occurrence might also explain the finding of pro-
tective effects of male sex for venous thrombosis, owing
that SVT occurred in females more than 90% of cases.
In conclusion, we report that patients with pre-PMF can
be accurately stratified in different risk categories for
cardiovascular events using the IPSET score as developed
for ET; possible refinements might derived from the
inclusion of leukocytosis28 and/or additional molecular
variables29, such as HMR mutations, and possibly other
mutations. Also, whether the same management approach
to minimize the risk of first or recurrent thrombosis that
are used for ET patients, based on the IPSET stratifica-
tion, results similarly effective in patients with pre-PMF
remains a research question for future studies17,30.
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